What kind of financial commitment has the Initiative received? What about non-financial?
Lilly has opened access to its greatest assets, a library of 500,000 compounds. The company is lending its immense drug discovery expertise and organizational savvy. It is contributing the latest, most innovative technologies used in drug discovery to be applied to the search for new drugs to fight TB. And, Lilly has given $15 million to support the historic undertaking. IDRI provides substantial expertise in microbiology, molecular biology and chemistry, as well as manages the Initiative’s own laboratory. It serves as the principal coordinator for all partnership efforts. NIH’s NIAID has a wide variety of existing resources that can be leveraged to develop a portfolio of prioritized and validated molecular targets and chemical hits. In fiscal year 2007, NIAID invested more than $47 million in almost 90 projects focused on TB drug development. The Microbial Chemistry Research Foundation of Tokyo and Summit plc of Oxfordshire, UK signed agreements for two compounds that have shown signi
